Summit Therapeutics Inc
SMMT24.120USD
+0.500+2.12%
收盘 04/30, 16:00（美东）报价延迟15分钟
17.79B总市值
亏损市盈率 TTM
关于 Summit Therapeutics Inc 公司
Summit Therapeutics Inc. 是一家专注于发现、开发和商业化患者、医生和护理人员药物疗法的生物制药公司。该公司的开发候选药物是 ivonescimab，这是一种潜在的同类首创双特异性抗体，旨在将通过阻断 PD-1 产生的免疫疗法效果与抗 VEGF 化合物的抗血管生成效果结合到单个分子中。该公司开发了用于非小细胞肺癌 (NSCLC) 的 ivonescimab，具体启动了以下适应症的 III 期临床试验，例如 ivonescimab 联合化疗用于表皮生长因子受体 (EGFR) 突变、局部晚期或转移性非鳞状 NSCLC 患者，这些患者在接受第三代 EGFR 酪氨酸激酶抑制剂 (HARMONi) 治疗后病情出现进展，以及 ivonescimab 联合化疗用于一线转移性鳞状 NSCLC 患者 (HARMONi-3)。其 ivonescimab 采用 Akeso 的 Tetrabody 技术设计。
公司简介
公司代码SMMT
公司名称Summit Therapeutics Inc
上市日期Oct 14, 2004
成立日期2020
CEODr. Mahkam (Maky) Zanganeh
员工数量159
证券类型Ordinary Share
年结日Oct 14
公司地址601 Brickell Key Drive
城市MIAMI
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编33131
电话13052032034
网址https://www.smmttx.com/
公司代码SMMT
上市日期Oct 14, 2004
成立日期2020
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Robert William (Bob) Duggan
Mr. Robert William (Bob) Duggan
Executive Chairman of the Board, Co-Chief Executive Officer
Executive Chairman of the Board, Co-Chief Executive Officer
555.68M
+0.72%
Dr. Mahkam (Maky) Zanganeh
Dr. Mahkam (Maky) Zanganeh
President, Co-Chief Executive Officer, Director
President, Co-Chief Executive Officer, Director
35.38M
+0.24%
Dr. Yu (Michelle) Xia
Dr. Yu (Michelle) Xia
Non-Executive Director
Non-Executive Director
31.52M
--
Mr. Manmeet S. Soni, CPA
Mr. Manmeet S. Soni, CPA
Chief Financial Officer, Chief Operating Officer, Director
Chief Financial Officer, Chief Operating Officer, Director
--
--
Mr. Robert Lacaze
Mr. Robert Lacaze
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Jeff Huber
Mr. Jeff Huber
Director
Director
--
--
Mr. Kenneth A. Clark, J.D.
Mr. Kenneth A. Clark, J.D.
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Robert F. Booth, Ph.D.
Dr. Robert F. Booth, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Mostafa Ronaghi, Ph.D.
Dr. Mostafa Ronaghi, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Robert William (Bob) Duggan
Mr. Robert William (Bob) Duggan
Executive Chairman of the Board, Co-Chief Executive Officer
Executive Chairman of the Board, Co-Chief Executive Officer
555.68M
+0.72%
Dr. Mahkam (Maky) Zanganeh
Dr. Mahkam (Maky) Zanganeh
President, Co-Chief Executive Officer, Director
President, Co-Chief Executive Officer, Director
35.38M
+0.24%
Dr. Yu (Michelle) Xia
Dr. Yu (Michelle) Xia
Non-Executive Director
Non-Executive Director
31.52M
--
Mr. Manmeet S. Soni, CPA
Mr. Manmeet S. Soni, CPA
Chief Financial Officer, Chief Operating Officer, Director
Chief Financial Officer, Chief Operating Officer, Director
--
--
Mr. Robert Lacaze
Mr. Robert Lacaze
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Jeff Huber
Mr. Jeff Huber
Director
Director
--
--
收入明细
单位: USD更新时间: 4月6日 周日
单位: USD更新时间: 4月6日 周日
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
暂无数据
地区USD
名称
营收
占比
Latin America
0.00
0.00%
业务
地区
暂无数据
股东统计
更新时间: 2月21日 周五
更新时间: 2月21日 周五
持股股东
股东类型
持股股东
股东统计
占比
Duggan (Robert William)
75.35%
Zanganeh (Mahkam)
4.80%
Xia (Yu)
4.27%
Baker Bros. Advisors LP
3.31%
The Vanguard Group, Inc.
1.58%
Other
10.68%
持股股东
股东统计
占比
Duggan (Robert William)
75.35%
Zanganeh (Mahkam)
4.80%
Xia (Yu)
4.27%
Baker Bros. Advisors LP
3.31%
The Vanguard Group, Inc.
1.58%
Other
10.68%
股东类型
股东统计
占比
Individual Investor
84.90%
Investment Advisor
4.57%
Hedge Fund
4.06%
Investment Advisor/Hedge Fund
3.86%
Research Firm
0.40%
Pension Fund
0.02%
Bank and Trust
0.02%
Sovereign Wealth Fund
0.01%
Other
2.16%
机构持股
更新时间: 1月20日 周一
更新时间: 1月20日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q1
403
717.89M
97.58%
+5.51M
2024Q4
388
717.73M
97.33%
+5.42M
2024Q3
325
708.90M
96.17%
+11.45M
2024Q2
260
692.13M
98.13%
+14.08M
2024Q1
228
669.32M
95.38%
+36.91M
2023Q4
210
620.08M
88.82%
-5.65M
2023Q3
205
616.45M
88.38%
+11.96M
2023Q2
199
619.05M
88.77%
+407.10M
2023Q1
178
604.96M
86.79%
+406.66M
2022Q4
154
191.34M
95.05%
+13.11M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Duggan (Robert William)
551.70M
74.81%
+3.33M
+0.61%
Sep 13, 2024
Zanganeh (Mahkam)
35.38M
4.8%
+84.32K
+0.24%
Apr 17, 2024
Xia (Yu)
31.52M
4.27%
--
--
Apr 17, 2024
Baker Bros. Advisors LP
24.42M
3.31%
--
--
Dec 31, 2024
The Vanguard Group, Inc.
11.67M
1.58%
+724.04K
+6.61%
Dec 31, 2024
Fidelity Management & Research Company LLC
8.02M
1.09%
-277.94K
-3.35%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
7.55M
1.02%
+402.22K
+5.63%
Dec 31, 2024
T. Rowe Price Associates, Inc.
6.47M
0.88%
+1.11M
+20.72%
Dec 31, 2024
State Street Global Advisors (US)
5.60M
0.76%
+2.13M
+61.54%
Dec 31, 2024
Geode Capital Management, L.L.C.
3.20M
0.43%
+101.04K
+3.26%
Dec 31, 2024
查看更多
持股ETF
更新时间: 4月6日 周日
更新时间: 4月6日 周日
机构名称
占比
Tema Oncology ETF
2.77%
Invesco Nasdaq Biotechnology ETF
1.46%
ProShares Ultra Nasdaq Biotechnology
1.42%
Range Cancer Immunotherapy ETF
1.24%
Virtus LifeSci Biotech Clinical Trials ETF
1.04%
SPDR S&P Biotech ETF
0.92%
Invesco NASDAQ Next Gen 100 ETF
0.89%
Invesco ESG NASDAQ Next Gen 100 ETF
0.67%
Direxion Daily S&P Biotech Bull 3X Shares
0.58%
Simplify Next Intangible Core Index ETF
0.35%
查看更多
Tema Oncology ETF
占比2.77%
Invesco Nasdaq Biotechnology ETF
占比1.46%
ProShares Ultra Nasdaq Biotechnology
占比1.42%
Range Cancer Immunotherapy ETF
占比1.24%
Virtus LifeSci Biotech Clinical Trials ETF
占比1.04%
SPDR S&P Biotech ETF
占比0.92%
Invesco NASDAQ Next Gen 100 ETF
占比0.89%
Invesco ESG NASDAQ Next Gen 100 ETF
占比0.67%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.58%
Simplify Next Intangible Core Index ETF
占比0.35%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据